Latest Close
$0.93
Stock Hub
TIVC
Tivic Health Systems, Inc.
Tivic Health Systems, Inc. operates as a late-stage immunotherapeutics company. Use the sections below to move between chart, technical analysis, fundamentals, and news.
1y Change
-$3.44 (-78.70%)
Market Cap
$2,678,773.00
Sector
Healthcare
Industry
Medical Devices
Recommendation
none
52W Range
$0.72 to $13.23
Target Mean Price
Not available
Beta
1.84
Trailing P/E
Not available
Forward P/E
-0.04
Price / Book
0.14
Company Overview
Tivic Health Systems, Inc. operates as a late-stage immunotherapeutics company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications. In addition, it offers CDMO services. The company was incorporated in 2016 and is based in San Antonio, Texas.